Aastrom Biosciences (ASTM) Q4/10 Results
February 28th, 2011
No comments
The net loss was $13.3M or $0.44 per share. Read more…
Categories: Aastrom Biosciences, Q2 Earnings, Stem Cell Research
Archive
Archive for February, 2011
BrainStorm Cell Therapeutics (OTCQB: BCLI) $3.6M Financing
February 28th, 2011
No comments
BCLI.OB entered into a private placement financing with gross proceeds of $3.6M from the sale and purchase price of $0.28 per share. Read more…
Categories: Financing, Nasdaq: BCLI.OB, Stem Cell Research
Senators to Debate Patent Bill
February 28th, 2011
No comments
The Senate on 2/28/11 will begin debating the patent reform bill. Read more…
NeoStem (AMEX: NBS) offers Stem Cell Security Service
February 28th, 2011
No comments
NBS hopes to widen the awareness and audience for its adult stem cell banking and cord blood banking programs. Read more…
Categories: AMEX: NBS
Cytori Therapeutics (CYTX) granted foundational Japanese Patent
February 27th, 2011
No comments
CYTX has been issued Patent #4653952 (the ’952 patent) from the Japan Patent Office Read more…
Our Regenerative Medicine Weekly Trend Line
February 27th, 2011
No comments
Some shares of stem-cell companies regained lost ground by Friday, 2/25/11, after being pushed up and down during the week. Read more…
Geron (GERN) Q4/10 Results
February 27th, 2011
No comments
Q4/10 reported a loss of $59.4M, or $0.59 a share. Read more…
Categories: NASDAQ: GERN, Quarterly Earnings, Stem Cell Research
Management Change, Fate Therapeutics CEO Exits
February 24th, 2011
No comments
Fate Therapeutics’ (San Diego-based developer of stem cell therapies) CEO Paul Grayson is leaving. Read more…
Categories: Fate Therapeutics, Management Change, Stem Cell Research
ImmunoCellular Therapeutics (IMUC.OB), $8.1M Financing
February 24th, 2011
No comments
IMUC.OB initiated a private placement financing of approximately $8.1M Read more…
Categories: Financing, ImmunoCellular Therapeutics, IMUC.OB, Stem Cell Research
BrainStorm (BCLI.OB) NurOwn™ inhibits Sciatic Nerve Injury
February 23rd, 2011
No comments
BCLI.OB’s intramuscular transplantation of autologous, astrocyte-like cells, NuOwn™ significantly inhibited the degeneration of Read more…
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.